Founder/CEO at Lumen Bio. I'm a quasi-outsider to the biopharma industry, interested in the economics of drug development.

Seattle, Washington USA
Joined August 2009
Brian Finrow retweeted
Replying to @AAMortazavi
2
1
15
1,336
Brian Finrow retweeted
I have now lost the last bit of respect I had left for Terence Tao! This is one of the most ridiculous arguments I have ever heard. He also clearly has little understanding of biomedicine. There are many drugs whose mechanisms of action we still don’t fully understand. In fact, even aspirin was used for decades before scientists established its principal mechanism of action! Currently used lithium drug still has no known mechanism of action! If you were a cancer patient or seriously ill, would you really care whether scientists fully understood how a drug worked if it could save your life? How can such brilliant people fall so deep into the abyss of coping? I suspect we will see much more of this as AI continues to challenge established intellectual hierarchies.
This is a slide from Terence Tao's 'Math 2.0' public lecture yesterday evening at Caltech. I am highly confident that, if the cure actually worked, almost any Stage 4 cancer patient would tell you that human comprehension of its mechanism is completely irrelevant to them.
137
144
38
1,715
109,704
Brian Finrow retweeted
Assorted things I've been mulling over regarding agents in the economy: • Companies are in some sense the original superintelligence. It's often the case that they can use their amortized cognitive surplus to advance their interests against those of certain consumers: relative to the optimization capacity of companies, consumers can be inattentive, underinformed, irrational, etc. (Think, say, of some of the classic insurance upsells at the end of a booking process, which is typically priced substantially above what a regular policy would cost.) Herbert Simon introduced the idea of bounded rationality, and firms often end up benefiting from it. Thanks to personal agents, we will probably get somewhat more rational in how we engage with companies. • How exactly will outcomes change? Well, certain kinds of price discrimination will work less well (how do coupons work if every agent hunts fastidiously for them?), and certain kinds of customer cross-subsidy will change (today, people who forget to cancel subscriptions subsidize those who don't). Taken across the economy as a whole, I'm not sure what the incidence of all of this will be. • In corporate strategy, people have long debated the relative importance of distribution and product quality. Perhaps you've made something better, but does anyone know about it? Won't people just continue to buy the ACME Corp Mousetraps? Personal agents will, I think, act as a kind of structural subsidy for product quality. How would markets look different if individuals always spent at least 10 hours researching their purchases? On the margin, focusing on making a product better is, I think, going to become a more effective strategy for companies. This is good! • It true, a corollary is that information about product quality will become more important and impactful. Today, most people have very limited ability to aggregate and integrate such data, but agents will have insatiable thirst for such signals. (It's often said that data is becoming more valuable because it helps in the training of models. That's obviously true, but I think there's a secondary way in which it's more valuable simply as a complement to cheaper intelligence.) • A big question is whether agents will increase superstar effects (rational agents all settle on the same product) or increase dispersion (because everyone has slightly different tastes and preferences, which agents are good at eliciting, finally overcoming the artificial clustering we've been subjected to). • Many internet companies have monetized demand routing, which is in turn often predicated on short attention spans. "I'll click on the first thing I see." This has led to some amount of inefficiency, as companies try to propitiate capricious ranking algorithms and incur various placement fees. It's not all deadweight loss (willingness to pay is itself a kind of signal, which is valuable to buyers), but it's not great. How will the nature and value of this routing change in a world of personal agents? I don't know the answer, but I think that the effects might be pretty big. • Much of what I'm writing hinges on the assumption that personal agents will be on the consumer's side. I suspect that that will be the winning strategy, but whether it's true, and what it means to be true, involves a lot of other questions. Taken as a whole, the market is a massively parallelized, decentralized, and highly imperfect value attribution machine, and, taking stock of all of the effects, it seems to me that the quality point may well be the biggest: that agents will change the nature of the backpropagation such that the rewards for better products increase. Maybe this is too optimistic, but I suspect (and hope) that companies that make things that they're proud of will feel that the universe is a little more partisan in their favor.
492
1,008
444
9,546
1,709,303
Brian Finrow retweeted
A real contribution of AI is showing the critical weaknesses of humans and human structures.
5
15
2
97
37,953
Brian Finrow retweeted
open-sourcing CTDs is extremely exciting. we have found clinical protocols available on clinicaltrials.gov to be extremely helpful at y-trap. this will be an OOM jump beyond that in utility, especially for lean teams without decades of regulatory experience.
Replying to @JacobTref
CTD Commons will preserve and publish regulatory knowledge from failed drug development programs so future teams can learn from precedent that is usually locked away, to help uncover effective treatments for patients faster. A CTD, or Common Technical Document, is a document that compiles the full journey of an investigational drug – everything from animal toxicology, manufacturing details, and, perhaps most usefully, correspondence with the FDA. Yet only a small fraction of that work appears in published papers. CTD Commons will test the possibility of acquiring CTDs from failed or shelved drug programs, and make them openly available for research and analysis, for everyone to use. @antonioregalado wrote about the project, and @RuxandraTeslo's essay on the topic, here: xitter.cf/antonioregalado/status…
2
8
588
Brian Finrow retweeted
CTD Commons will preserve and publish regulatory knowledge from failed drug development programs so future teams can learn from precedent that is usually locked away, to help uncover effective treatments for patients faster. A CTD, or Common Technical Document, is a document that compiles the full journey of an investigational drug – everything from animal toxicology, manufacturing details, and, perhaps most usefully, correspondence with the FDA. Yet only a small fraction of that work appears in published papers. CTD Commons will test the possibility of acquiring CTDs from failed or shelved drug programs, and make them openly available for research and analysis, for everyone to use. @antonioregalado wrote about the project, and @RuxandraTeslo's essay on the topic, here: xitter.cf/antonioregalado/status…
OpenAI Foundation owns 26% of OpenAI. Could be the richest nonprofit/charity in the world? This year, it's staffing up and started giving grants. We wrote about grants to ramp up biological data production. technologyreview.com/2026/09…
4
12
6
57
11,308
Brian Finrow retweeted
We already know what a world without work looks like. It's the life of 18th century aristocrats, who concerned themselves with political gossip and petty dramas; of society ladies in the 1980s, who spent their time hosting and volunteering; and Italian-Americans in 1950s Boston, whose status was centered around their peer groups, rather than their jobs. Relational living comes to us naturally, but – argues @clarabcollier – work offers us dignity, structure, and meaning, as evinced by surveys that consistently find that about 85% of Americans are "somewhat" or "completely" satisfied by their jobs. Work gives us an escape from the cliquishness of relational societies: without it, our personal relationships might become even more stifling and transactional.
28
97
74
1,160
414,763
Brian Finrow retweeted
Huge get. Dan is great and has led some of the most innovative work at the Gates Foundation in recent years. Excited to continue working with him in this new role!
I’m incredibly excited that Dan Wattendorf is joining OpenAI Foundation as our Head of Bio-Resilience. As AI capabilities advance, biology could become one of the most consequential areas - for both extraordinary benefits and serious risks. We need to build the institutions and technologies that will help the world prepare. Dan has a rare combination of scientific judgment and the ability to make ambitious things happen. He helped pioneer DARPA’s early mRNA technology, served as a US Air Force colonel, and led the Gates Foundation’s Global Health Accelerator. There is an enormous amount to build, and I’m very glad Dan will be leading the charge.
2
33
4,749
Man we did a corruption for this?
2
1
364
Brian Finrow retweeted
Neat paper: Women lose weight: - Life drastically changes - Men start approaching, a third partner off ASAP Men lose weight: - Their weight decreases
GLP1s for weight loss impact lives beyond health. My new paper shows single women’s marriage/cohabitation rates rise 29pp, employment among nonemployed women rises 27 percentage points after 1.5+ years. Link to paper below:
173
602
90
14,681
2,475,529
Brian Finrow retweeted
This is one of the reasons we were excited to invest in @CurevoVaccine (recently announced acquisition by Eli Lilly). An improved shingles vaccine could have a huge impact on public health. Every day, we learn more about the impacts of viral infections on our long-term health. I predict preventing them will become more and more of a priority for the industry in the coming years.
Super weird, and potentially wonderful. We now have several natural experiments suggesting that the shingles vaccine significantly reduces dementia risk, or delays dementia risk, potentially by suppressing reactivation of the underlying virus, which can linger in nerve tissue and cause brain damage
1
1
1
9
2,435
Brian Finrow retweeted
Replying to @AndrewE_Dunn
What’s driving these changes? You can outsource early stage science to China for 1/5 of the cost at 2x the speed.
5
4
1
31
7,594
Writing again here with my friend Kevin Klowden (@MilkenInstitute) in @dddmag:  the twin challenges of AI drug design and China's advent as a drug-development superpower are causing interesting changes in the U.S. biopharma innovation ecosystem has a complex ecology. Lots of subtle implications for patent defensibility, and therefore biotech business models. We discuss 3 examples of how some innovative companies are responding (including Seattle's @VariantBio and @LumenBio, naturally).
1
2
146
Brian Finrow retweeted
The largest and sharpest image ever taken of the Andromeda galaxy — otherwise known as M31. It is the biggest Hubble image ever released and shows over 100 million stars, thousands of star clusters in a section of the galaxy’s disc stretching across over 40 000 light-years.
135
887
63
4,961
170,208
Pitch-perfect language here from the House Appropriations Committee for anyone interested in restoring U.S. competitiveness in early-stage drug development. They've clearly got someone with deep expertise helping out. @RuxandraTeslo & @joshcmorrison? 😉
2
3
1
26
5,088
If we lose to China in biotech, the proximal, nucleating cause, will be the failure of our regulatory apparatus to respond with a more decentralized, IRB and Investigator-driven, fast path to human proof of concept, without massive manufacturing burden. Fix it.
133
Brian Finrow retweeted
This is a hilariously disappointing result: 15% of placebo GLP-1 patients seemingly realized they weren't getting the real stuff and so they went out and got it on their own. They're undermining the trials because they want to lose weight!
🔔Survodutide SYNCHRONIZE-1 full paper is out for Boehringer-Ingelheim’s GLP-1/Glucagon study for weight loss. ▪️13% loss on 6mg (treatment regimen estimand) ▪️Huge treatment discontinuations due to AEs: 20% ▪️Nausea 65%, Vomiting 45% ▪️Placebo was killer. 5.4% WL. Wow. ▪️60% women ▪️Very global study
62
158
22
3,442
365,445